Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.
Jun 2018 | FROM EXTERNAL EXPERTS
Recent advances in understanding and managing non-alcoholic fatty liver disease
Jan 2018 | From External Experts
Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
Jan 2018 | FROM EXTERNAL EXPERTS
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Apr 2017 | FROM EXTERNAL EXPERTS
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists
Jan 2017 | From External Experts
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
Nov 2016 | FROM EXTERNAL EXPERTS
An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function
![PSB-Image-Pipeline](https://akerotx.com/wp-content/uploads/2021/08/PSB-Image-Pipeline.jpg)
![PSB-Image-Pipeline](https://akerotx.com/wp-content/uploads/2021/08/PSB-Image-Pipeline.jpg)